rs869312161
Variant summary
Our verdict is Uncertain significance. The variant received 3 ACMG points: 5P and 2B. PM1PM2PP2BP4_Moderate
The NM_000169.3(GLA):c.989A>G(p.Gln330Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 16/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q330E) has been classified as Uncertain significance.
Frequency
Consequence
NM_000169.3 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 3 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GLA | NM_000169.3 | c.989A>G | p.Gln330Arg | missense_variant | Exon 6 of 7 | ENST00000218516.4 | NP_000160.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD2 exomes AF: 0.00 AC: 0AN: 183449 AF XY: 0.00
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1086229Hom.: 0 Cov.: 29 AF XY: 0.00 AC XY: 0AN XY: 352607
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Fabry disease Uncertain:3
GLA c.989A>G is a missense variant that changes the amino acid at residue 330 from Glutamine to Arginine. This variant has been observed in at least one proband affected with Fabry disease (PMID:26415523;30739116). Functional studies have been reported; however, the significance of the findings remain unclear (PMID:26415523). It is absent or not present at a significant frequency in gnomAD. In silico models agree that this variant is not damaging. In conclusion, we classify GLA c.989A>G as a variant of unknown significance.
The p.Gln330Arg variant in GLA has been reported in the literature in three males, whose clinical status for Fabry disease was uncertain (PMID: 26415523, 29330335, 28340804), and was absent from large population studies (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs869312161). This variant has also been reported in ClinVar as a VUS by the Albrecht-Kossel-Institute (Variation ID: 217409). In vitro functional studies provide some evidence that the p.Gln330Arg variant may not impact protein function (PMID: 26415523). However, these types of assays may not accurately represent biological function. Computational prediction tools, including splice predictors, and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of p.Gln330Arg is uncertain. ACMG/AMP Criteria applied: PM2, BP4, BS3_supporting (Richards 2015).
Migalastat response Other:1
Pharmacological Chaperone response: yes
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at